Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PEPTONIC Medical AB (publ) YEAR END REPORT  Period january – december 2022

GROUP 2022 FOURTH QUARTER (oct-dec) · Net sales of products 10 191 (5 642) tkr · Gross profit 4 302 (3 388) tkr, 42% (60%) · Adjusted gross profit 5 313 (3 388) tkr, 52% (60%)[i] · Operating loss -6 890 (-43 974) tkr · Loss per share -0,03 (-0,23) kr FULL YEAR 2022 (jan-dec) · Net sales of products 43 634 (31 643) tkr · Gross profit 23 394 (19 070) tkr, 54% (60%) · Operating loss -33 606 (-73 718) tkr · Loss per share -0,15 (-0,38) kr [i] Before inventory adjustments that fully charge quarter 4 instead of being distributed over previous quarters.From

NYAB Plc and Andament Group Oy have signed a merger plan, whereby the company demerging from Andament Group Oy merges into NYAB Plc

NYAB PlcCOMPANY ANNOUNCEMENT24 February 2023 at 17:00NYAB Plc and Andament Group Oy have signed a merger plan, whereby the company demerging from Andament Group Oy merges into NYAB Plc · NYAB Plc’s and Andament Group Oy’s Boards of Directors have signed a merger plan that aims at clarifying the ownership structure of NYAB Plc and expanding its owner base. · In the proposed series of transactions, 111,000,000 shares in NYAB Plc that Andament owns, corresponding to 15.7% of all shares in the Company, are cancelled, and the equivalent number of new shares in the Company will be

Annual general meeting in Heimstaden AB (publ)

The shareholders of Heimstaden AB (publ), reg.no. 556670-0455 (the “Company”), are hereby summoned to the annual general meeting on Thursday 30 March 2023, at 10:00 a.m. CET at the Company’s premises on Östra Promenaden 7 A, SE-211 28 Malmö. Registration for the general meeting will commence at 09:30 a.m. CET.Notice of attendance etc. Shareholders who wish to attend and vote at the general meeting must: both be entered in the share register kept by Euroclear Sweden AB on Wednesday 22 March 2023, or, if the shares are nominee-registered, request that the nominee registers the shares

Eevia Health Plc Interim Report Q4 - 2022

Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the fourth quarter of 2022. Summary of the fourth quarter 2022 (Q4-22):· Net sales[1] grew by 115% from KEUR 658 in Q4-21 to KEUR 1 420 in Q4-22. Excluding one-off charges of KEUR 143 in Q4-21, net sales increased by 77%, from KEUR 800 in Q4-21 to KEUR 1 418 in Q4-22. · The gross profit in Q4-22 came in at KEUR 966, an improvement of 575% from KEUR 168 in Q4-21. The gross profit constitutes a gross margin[2] of 68%, a significant improvement over Q4-21 (21%) and Q3-22 (63%). The improvement is

Heimstaden Bostad: Annual and Sustainability Report 2022

2022 Highlights: · Strong operational result with rental income of SEK 12.7 billion (8.6) and like-for-like growth of 5.4% (2.5%). · SEK 5.1 billion negative fair value adjustment while a weaker SEK gave a net positive FX effect of SEK 7.1 billion. · Comprehensive income SEK 8.4 billion. · Investment properties SEK 345 billion (158,326 homes). · Real economic occupancy 98.4% (97.9%). · Net LTV 50.3% (46.2%) and ICR 3.4x (4.1x). · Raised SEK 15 billion equity from existing equity partners. · Closed second partnership with Allianz in December. · Buybacks of bonds in

Heimstaden: Annual and Sustainability Report 2022

2022 Highlights: · Strong operational result with rental income of SEK 13.2 billion (9.0) and like-for-like growth of 5.4% (2.5%). · SEK 4.2 billion negative fair value adjustment while a weaker SEK gave a net positive FX effect of SEK 6.6 billion. · Comprehensive income SEK 8.1 billion. · Investment properties SEK 351 billion (160,003 homes). · Real economic occupancy 98.4% (97.8%). · Net LTV 53.6% (51.0%) and ICR 2.4x (3.2x). · SEK 580 million buyback of bonds in December. · Heimstaden Bostad raised SEK 15 billion equity from existing equity partners, including SEK

Resqunit AB - Half Year Report H2-2022

Resqunit AB Half Year Interim Report H2-2022Resqunit AB (publ) ("Resqunit") February 24rd, 2023, at 15.30 CET - publishes Half Year Interim Report H2-2022 Second half year 2022 - compared to second half year 2021 Group revenue have been limited in both periods.Operating profit amounted to -4,194 kSEK (-6,141 kSEK)Earnings per share -0,40 SEK (-0,58 SEK ) Key figures (SEK) Jul-Dec 2022, Group, unaudited (Jul-Dec 2021, Group Proforma, unaudited)Net sales, SEK    296,435    (0)Operating profit    SEK    -4,193,865    (-6,141,967)Earnings per share    -0,40    (-0,58)

YrkesAkademin receives consent from bondholders to amend the terms and conditions of its outstanding bond loan

YA Holding AB (publ) (“YA” or the “Company”) announces that the written procedure initiated through a notice to the bondholders on 7 February 2023 (the “Written Procedure”) regarding certain amendments to the terms and conditions of the Company’s outstanding bond loan with ISIN SE0016831150 (the “Bonds”) has today been completed. The quorum was reached and a requisite majority of the voting bondholders voted in favour of the Company’s request under the Written Procedure. The bondholders under the Bonds have therefore consented to the proposed amendments as set out in the notice of the

AstraZeneca acquires CinCor for cardiorenal asset

24 February 2023 14:05 GMT Acquisition of CinCor Pharma complete AstraZeneca announced today the successful completion of the acquisition of CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. Baxdrostat

Family Fun at Jarrow Hall

24/02/2023  Jarrow Hall reopened after it’s Winter break on February 18th. This year we have lots of exciting things in store making it a great place to visit for families. As part of World Book Weekend, starting on Thursday 2nd March to Sunday March 5th, you can go undercover and test your detective skills at Jarrow Hall as part of the national Montgomery Bonbon: Museum Mystery Trail, organised by Kids in Museums and Walker Books. The trail celebrates the release of new children’s book Montgomery Bonbon: Murder at the Museum written by comedian Alasdair Beckett-King and illustrated

Chief Strategy Officer Haydn Povey leaves IAR

Uppsala, Sweden—February 24, 2023 – IAR, the world leader in software and services for embedded development, today announces that the company’s Chief Strategy Officer, Haydn Povey, has decided to leave IAR at his own request. Haydn Povey was the Founder and CTO of SecureThingz from 2016 until the acquisition by IAR in 2018 when he became Chief Strategy Officer at IAR. Haydn is a well-known security expert and has held senior positions at global technology companies for over 20 years, including Arm, and is a Board member of the IoT Security Foundation. “I’m sorry that Haydn has decided

United Bankers Plc’s Annual Report for 2022 has been published

United Bankers Plc STOCK EXCHANGE RELEASE 24 February 2023 at 16.00 EET     United Bankers Plc’s Annual Report for 2022 has been published United Bankers Plc’s Annual Report, Corporate Governance Statement, and Remuneration Report for 2022 have been published in Finnish and English on the company’s website www.unitedbankers.fi  and as separate pdf-versions attached to this stock exchange release. The Annual Report consists of the Board of Directors’ Report, the Auditor’s Report, and the Financial Statements for 2022. United

NCC signs installation contract for New North Zealand Hospital

NCC and the Capital Region of Denmark have signed an installation contract in conjunction with the construction of New North Zealand Hospital in Denmark. The order value for the installation contract amounts to approximately SEK 1.7 billion. Photo: Jonathan Grevsen NCC has been conducting construction work on New North Zealand Hospital in Denmark for the past three years. Construction of the super hospital has now reached the point that it is ready for the installation stage involving plumbing, ventilation and electricity. “We’ve had a close and trusting collaboration with

Veidekke: To renovate and remodel school in Vallentuna, Sweden

Veidekke's Swedish subsidiary Arcona has been commissioned by Vallentuna municipality to renovate and remodel Vallentuna upper secondary school, which in future will house both the school and municipality offices. The collaborative design and build contract is worth approx. SEK 190 million, of which the design phase has already been completed and amounts to approx. SEK 15 million.The approx. 9,000 m[2] school building will be renovated and converted into modern premises suitable for students as well as for municipality employees. The project also comprises a car park for employees and a new

Handelsbanken publishes its Annual and Sustainability Report and annual reports for 2022

“No matter how things evolve in the world around us, we are always able to do the business that we, and our customers, want. Our very strong finances give us, among other things, higher ratings, compared to our competitors. And, perhaps most significantly: greater freedom to do more business”, says Carina Åkerström, President and Group Chief Executive Officer Handelsbanken. Read more in Handelsbanken's Annual and Sustainability Report . Today Handelsbanken has also published its Sustainability Fact book, Climate change progress report

EPO announces intention to grant BMB an additional patent

The European patent office (EPO) has announced its intention to grant another patent for Biomedical Bonding AB. The patent is entitled “A composition comprising thiol, alkene and phosphonic acid containing compounds for use as a primer for adhesion improvement”."This patent further strengthens Biomedical Bonding’s Bonevolent™ patent portfolio with emphasis on novel primers and their use in bone fixation and restoration treatments. The Bonevolent™ technology is founded on resin-composites with increased biocompatibility, tissue-friendliness, and high mechanical strength” comments Evelina

Publication of the documents for AGM 2023 in Misen Energy AB (publ)

The following documents are enclosed to this press release and have been published today in Swedish and English on the company’s website at http://misenenergy.se/en/main/corporate_governance/agm: - the nomination committee’s full proposal to AGM 2023,- principles for the nomination committee,- proxy voting form. All documents are also attached to this press release and are available at the company‘s offices at Kungsportsavenyen 32, SE-411 36, Gothenburg, Sweden and at the offices of Baker & McKenzie Advokatbyrå at Vasagatan 7, SE-101 23 Stockholm, Sweden and will upon request be

Eevia Health Plc receives a new and more recognized Kosher certificate

Eevia Health Plc, (”Eevia” or ”The Company”), has been certified by OK Kosher, US.Eevia had earlier a Kosher certification from OK Kosher in New York, but this certification was discontinued in 2021 and replaced with a local Kosher certificate from the Jewish Community of Helsinki. However, multiple prospects with whom Eevia discusses larger business contracts did not accept the local Kosher certificate. They required a Kosher certificate from one of the "Big Five" Kosher certification agencies. These are the largest Kosher certification agencies, certifying more than 80% of the Kosher food

DanCann Pharma A/S: The first repackaging process has been completed at the new CannGros ApS facilities in Ansager

COPENHAGEN, Denmark, 24 February 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that The Company has successfully completed its first repackaging process at its new facilities in Ansager, where its subsidiary, CannGros ApS ("CannGros"), obtained approval for its facilities at the end of 2022.The past few months have been dedicated to preparing for our first production, including the establishment of a quality management system (QMS) and training of personal in standard operating procedures

BEWI – New share capital registered

Reference is made to the stock exchange notice by BEWI ASA (BEWI or the Company) on 18 February 2023 regarding the share capital increase resolved by the board of directors upon the exercise of options under the Company's share option programme. The share capital increase pertaining to the issuance of the new shares has been registered with the Norwegian Register of Business Enterprises: Share capital (new): NOK 191,722,290 Total number of shares (new): 191,722,290 Par value of each share: NOK 1.00 Contact: Charlotte Knudsen, Director of IR and Communications BEWI ASA, tel:

Extension to Relais Group Plc’s Facilities agreement

Relais Group Plc, Stock Exchange Release24 February 2023 at 1.30 p.m. EET Relais Group Plc has agreed on extension of its Facilities Agreement originally concluded in 2019 and last amended in March 2022 with its main bank. The maturity of the agreement has been extended by one year until 31 May 2025. The previous maturity date of the Facilities Agreement was 31 May 2024. Except for certain amended specifications and definitions related to Relais Group Plc’s IFRS transition announced on 25 October 2022, the key terms of the Amended and Restated Facilities Agreement remain mainly

Thailand wins the "Best Tourist Country" once again at Grand Travel Award 2023 in Sweden

Thailand wins “Best Tourist Country" once again in the last 5 years. The honor was given at Grand Travel Award in Stockholm, Sweden on 23rd February 2023  Ms. Krittika Rojanasap, Deputy Director of TAT Stockholm office and Mrs. Kantara Olofsson, PR & Communications officer (middle) together with Ms. Thanida Menasavet, Minister Counselor (left) and Mrs. Chinattha Sangvachara, Second Secretary (right) representative from the Royal Thai Embassy in Stockholm   30th Grand Travel Award 2023 organized by TravelNews, who annually arranges the prestigious Award Gala. The result is

Idogen publishes interim report for 1 January – 31 December 2022

Idogen AB's interim report for January to December 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/   Fourth quarter (October-December 2022) • Other operating income amounted to KSEK 256 (3,335) • Operating loss was KSEK -11,759 (-13,552) • Loss for the quarter totaled KSEK -11,465 (-13,529) • Cash flow from operating activities was KSEK -12,591 (-15,074) • Loss per share before dilution was SEK -0.16 (-0.61). Loss per share after dilution was SEK -0.16 (-0.61) • The proposed dividend is SEK 0.00/share (0.00)

There are no items matching the current filter
There are no more items matching the current filter
Back to top